Adaptimmune Therapeutics АДР (ADAP) Nyanmɛn Kpɛn

Adaptimmune Therapeutics

Healthcare · USD · United States of America

Nɛnɛn kpanlan$0.03Kpɛn 25 Sep 2026

Chɛ̀ndʒ+50.00%

AI bɛ́nɛ́nɛ́: ADAP

1 jɔ̀rnɛ̀l

🔒 Yɛ́lɛ́ Premium

1 sɛ̀mɛ̀n

🔒 Yɛ́lɛ́ Premium

1 mɔ̀sɔ̀

🔒 Yɛ́lɛ́ Premium

AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.

Prix su les 6 mois derniers

Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.

Yɛ́lɛ́ Premium

🔒 Nzɛnkan nyinmɛn

Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.

Yɛ́lɛ́ Premium

Nyanmiɛn nɛnɛn

Adaptimmune Therapeutics is a biotechnological company that develops immunotherapy based on T -cells for the treatment of cancer.

Stocks sɛn nyɛ

TXG10X Genomics Inc Nɛnɛn kpanlan$85.71 +1.90%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ABTAbbott Nɛnɛn kpanlan$101.31 +0.24%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ABBVAbbVie Nɛnɛn kpanlan$264.31 -0.31%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ABCLAbCellera Biologics Nɛnɛn kpanlan$12.72 +0.47%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ACADACADIA Pharmaceuticals Inc Nɛnɛn kpanlan$20.68 -6.76%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ACMRACM Research Inc Nɛnɛn kpanlan$77.34 +1.52%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ADPTAdaptive Biotechnologies Nɛnɛn kpanlan$29.45 -0.41%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

ADUSAddus HomeCare Corp Nɛnɛn kpanlan$113.07 -0.84%AI bɛ́nɛ́nɛ́ · 1 jɔ̀rnɛ̀l🔒 Premium

Sù AI Stock Predictions

Download our app for AI stock forecasts nɛ iPhone, Android anɛ Windows

Yɛ́lɛ́ Premium

Disclaimer: AI-generated stock predictions nɛ a yɛ for informational purposes only anɛ do not constitute financial advice. Past performance does not guarantee future results. Always do your own research anɛ consult a qualified financial advisor before making investment decisions. Investing involves risk, including possible loss of principal.